Companies: 48,687 Total Market Cap: 126956050782004.97

Samsung Biologics Co.,Ltd.

KRX-207940
Healthcare Biotechnology
Rank #373
Market Cap 54.83 B
Volume 39.21
Price 746.92
Change (%) 0.09%
Country or region South Korea South Korea

Samsung Biologics Co.,Ltd.'s latest marketcap:

54.83 B

As of May 2, 2025, Samsung Biologics Co.,Ltd.'s market capitalization has reached $54.83 B. According to our data, Samsung Biologics Co.,Ltd. is the 373th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 54.83 B
Revenue (ttm) 3.23 B
Net Income (ttm) 769.15 M
Shares Out 71.17 M
EPS (ttm) 10.81
Forward PE 58.07
Ex-Dividend Date n/a
Earnings Date April 23, 2025
Market Cap Chart
Data Updated: May 2, 2025

Samsung Biologics Co.,Ltd.'s yearly market capitalization.

Samsung Biologics Co.,Ltd. has seen its market value grow from ₩54,652.29 B to ₩73,807.44 B since 2020, representing a total increase of 35.05% and an annual compound growth rate (CAGR) of 7.19%.
Date Market Cap Change (%)
April 28, 2025 ₩73,807.44 B 9.27%
December 30, 2024 ₩67,544.13 B 24.87%
December 28, 2023 ₩54,092.24 B -7.43%
December 29, 2022 ₩58,433.85 B -2.2%
December 30, 2021 ₩59,747.00 B 9.32%
December 30, 2020 ₩54,652.29 B

Company Profile

About Samsung Biologics Co., Ltd.

Samsung Biologics Co., Ltd., along with its subsidiaries, specializes in the manufacturing of biopharmaceutical products. Headquartered in Incheon, South Korea, the company operates globally, serving markets in Europe, the United States, and beyond.

Business Segments

  • Contract Development and Manufacturing Organization (CDMO): Provides end-to-end biopharmaceutical manufacturing solutions.
  • Biopharmaceutical Development and Commercialization: Focuses on biosimilar drugs, antibody-drug conjugates, and mRNA products.

Key Services

  • Development Services: Late discovery, cell line development, process development, analytical development, and non-GMP/CGMP manufacturing.
  • Manufacturing & Support: Aseptic filling, lyophilization, finishing, storage, shipping, and regulatory support.
  • Quality & Testing: Biosafety testing, analytical testing, and drug substance manufacturing.

Founded in 2011, Samsung Biologics has established itself as a leader in the biopharmaceutical industry, delivering innovative and high-quality solutions.

Frequently Asked Questions

As of May 2, 2025, Samsung Biologics Co.,Ltd. (including the parent company, if applicable) has an estimated market capitalization of $54.83 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

Samsung Biologics Co.,Ltd. global market capitalization ranking is approximately 373 as of May 2, 2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region South Korea
Founded 2011
IPO Date n/a
Employees 4,770
CEO John Chongbo Rim
Sector Healthcare
Industry Biotechnology
Address 300, Songdo bio-daero
Incheon
South Korea
People Also Watch
VRTX
501.15 0.09%
ASX-CSL
165.14 0.09%
REGN
605.61 0.09%
ARGX
649.67 0.09%